 Connection
Terry Fry to Graft vs Host Disease
This is a "connection" page, showing publications Terry Fry has written about Graft vs Host Disease.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.782 |
|
|
|
-
Shah NN, Watson TM, Yates B, Liewehr DJ, Steinberg SM, Jacobsohn D, Fry TJ. Procalcitonin and cytokine profiles in engraftment syndrome in pediatric stem cell transplantation. Pediatr Blood Cancer. 2017 03; 64(3).
Score: 0.462
-
Jacoby E, Yang Y, Qin H, Chien CD, Kochenderfer JN, Fry TJ. Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood. 2016 Mar 10; 127(10):1361-70.
Score: 0.435
-
Capitini CM, Nasholm NM, Chien CD, Larabee SM, Qin H, Song YK, Klover PJ, Hennighausen L, Khan J, Fry TJ. Absence of STAT1 in donor-derived plasmacytoid dendritic cells results in increased STAT3 and attenuates murine GVHD. Blood. 2014 Sep 18; 124(12):1976-86.
Score: 0.395
-
Shand JC, Qin H, Nasholm N, Capitini CM, Fry TJ. Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T Cells. Biol Blood Marrow Transplant. 2014 Jan; 20(1):26-36.
Score: 0.375
-
Capitini CM, Nasholm NM, Duncan BB, Guimond M, Fry TJ. Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis. J Immunol. 2013 Feb 01; 190(3):1351-9.
Score: 0.354
-
Capitini CM, Davis JP, Larabee SM, Herby S, Nasholm NM, Fry TJ. Extracorporeal photopheresis attenuates murine graft-versus-host disease via bone marrow-derived interleukin-10 and preserves responses to dendritic cell vaccination. Biol Blood Marrow Transplant. 2011 Jun; 17(6):790-9.
Score: 0.309
-
Capitini CM, Herby S, Milliron M, Anver MR, Mackall CL, Fry TJ. Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect. Blood. 2009 May 14; 113(20):5002-9.
Score: 0.272
-
Fierro-Pineda JC, Tsai HL, Blackford A, Cluster A, Caywood E, Dalal J, Davis J, Egeler M, Huo J, Hudspeth M, Keating A, Kelly SS, Krueger J, Lee D, Lehmann L, Madden L, Oshrine B, Pulsipher MA, Fry T, Symons HJ. Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias. Blood Adv. 2023 09 26; 7(18):5639-5648.
Score: 0.187
-
Kitko CL, Bollard CM, Cairo MS, Chewning J, Fry TJ, Pulsipher MA, Shenoy S, Wall DA, Levine JE. Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30577.
Score: 0.184
-
Patterson MT, Khan SM, Nunes NS, Fletcher RE, Bian J, Hadjis AD, Eckhaus MA, Mendu SK, de Paula Pohl A, Venzon DJ, Choo-Wosoba H, Ishii K, Qin H, Fry TJ, Cam M, Kanakry CG. Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects. Blood. 2023 02 09; 141(6):659-672.
Score: 0.179
-
Shah NN, Loeb DM, Khuu H, Stroncek D, Ariyo T, Raffeld M, Delbrook C, Mackall CL, Wayne AS, Fry TJ. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse. Biol Blood Marrow Transplant. 2016 12; 22(12):2149-2154.
Score: 0.115
-
Yang Y, Jacoby E, Fry TJ. Challenges and opportunities of allogeneic donor-derived CAR T cells. Curr Opin Hematol. 2015 Nov; 22(6):509-515.
Score: 0.108
-
Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, Lemberg K, Hurley CK, Kleiner DE, Merchant MS, Pittaluga S, Sabatino M, Stroncek DF, Wayne AS, Zhang H, Fry TJ, Mackall CL. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood. 2015 Jan 29; 125(5):784-92.
Score: 0.101
-
Dean RM, Fry T, Mackall C, Steinberg SM, Hakim F, Fowler D, Odom J, Foley J, Gress R, Bishop MR. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol. 2008 Dec 10; 26(35):5735-41.
Score: 0.067
-
Fry TJ, Lankester AC. Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology? Pediatr Clin North Am. 2008 Feb; 55(1):147-67, xi.
Score: 0.063
-
Fry TJ, Mackall CL. Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future. Bone Marrow Transplant. 2005 Mar; 35 Suppl 1:S53-7.
Score: 0.052
-
Sinha ML, Fry TJ, Fowler DH, Miller G, Mackall CL. Interleukin 7 worsens graft-versus-host disease. Blood. 2002 Oct 01; 100(7):2642-9.
Score: 0.044
-
Melendez-Munoz R, Marchalik R, Jerussi T, Dimitrova D, Nussenblatt V, Beri A, Rai K, Wilder JS, Barrett AJ, Battiwalla M, Childs RW, Fitzhugh CD, Fowler DH, Fry TJ, Gress RE, Hsieh MM, Ito S, Kang EM, Pavletic SZ, Shah NN, Tisdale JF, Gea-Banacloche J, Kanakry CG, Kanakry JA. Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution. Biol Blood Marrow Transplant. 2019 03; 25(3):577-586.
Score: 0.033
-
Chung YJ, Fry TJ, Aplan PD. Myeloablative hematopoietic stem cell transplantation improves survival but is not curative in a pre-clinical model of myelodysplastic syndrome. PLoS One. 2017; 12(9):e0185219.
Score: 0.031
-
Mackall C, Fry T, Gress R, Peggs K, Storek J, Toubert A. Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant. 2009 Oct; 44(8):457-62.
Score: 0.018
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|